Literature DB >> 25790037

Neurological complications after liver transplantation as a consequence of immunosuppression: univariate and multivariate analysis of risk factors.

Gianluca Rompianesi1, Roberto Montalti1, Nicola Cautero1, Nicola De Ruvo1, Anthony Stafford2, Carolina Bronzoni3, Roberto Ballarin1, Lesley De Pietri4, Fabrizio Di Benedetto1, Giorgio E Gerunda3.   

Abstract

Neurological complications (NCs) can frequently and significantly affect morbidity and mortality of liver transplant (LT) recipients. We analysed incidence, risk factors, outcome and impact of the immunosuppressive therapy on NC development after LT. We analysed 478 LT in 440 patients, and 93 (19.5%) were followed by NCs. The average LOS was longer in patients experiencing NCs. The 1-, 3- and 5-year graft survival and patient survival were similar in patients with or without a NC. Multivariate analysis showed the following as independent risk factors for NC: a MELD score ≥20 (OR = 1.934, CI = 1.186-3.153) and an immunosuppressive regimen based on calcineurin inhibitors (CNIs) (OR = 1.669, CI = 1.009-2.760). Among patients receiving an everolimus-based immunosuppression, the 7.1% developed NCs, vs. the 16.9% in those receiving a CNI (P = 0.039). There was a 1-, 3- and 5-year NC-free survival of 81.7%, 81.1% and 77.7% in patients receiving a CNI-based regimen and 95.1%, 93.6% and 92.7% in those not receiving a CNI-based regimen (P < 0.001). In patients undergoing a LT and presenting with nonmodifiable risk factors for developing NCs, an immunosuppressive regimen based on CNIs is likely to result in a higher rate of NCs compared to mTOR inhibitors.
© 2015 Steunstichting ESOT.

Entities:  

Keywords:  calcineurin inhibitors; immunosuppression; liver transplantation; mTOR inhibitors; neurological complications

Mesh:

Substances:

Year:  2015        PMID: 25790037     DOI: 10.1111/tri.12564

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

1.  Factors Associated With Neurobehavioral Complications in Pediatric Abdominal Organ Transplant Recipients Identified Using Computable Composite Definitions.

Authors:  Alicia M Alcamo; Robert S B Clark; Alicia K Au; Sajel Kantawala; Eric J Yablonsky; Rakesh Sindhi; George V Mazariegos; Rajesh K Aneja; Christopher M Horvat
Journal:  Pediatr Crit Care Med       Date:  2020-09       Impact factor: 3.971

2.  Liver Transplant Patients with High Preoperative Serum Bilirubin Levels Are at Increased Risk of Postoperative Delirium: A Retrospective Study.

Authors:  Kyu Hee Park; Hyo Jung Son; Yoon Ji Choi; Gene Hyun Park; Yoon Sook Lee; Ju Yeon Park; Hyun-Su Ri; Jae Ryong Shim
Journal:  J Clin Med       Date:  2020-05-24       Impact factor: 4.241

3.  Cerebral metabolite alterations in patients with posttransplant encephalopathy after liver transplantation.

Authors:  Henning Pflugrad; Anita Blanka Tryc; Annemarie Goldbecker; Hannelore Barg-Hock; Christian Strassburg; Jürgen Klempnauer; Heinrich Lanfermann; Karin Weissenborn; Peter Raab
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

4.  Quantitative magnetic resonance imaging indicates brain tissue alterations in patients after liver transplantation.

Authors:  Lukas Laurids Goede; Henning Pflugrad; Birte Schmitz; Heinrich Lanfermann; Anita Blanka Tryc; Hannelore Barg-Hock; Jürgen Klempnauer; Karin Weissenborn; Xiao-Qi Ding
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

5.  Reduced microglia activity in patients with long-term immunosuppressive therapy after liver transplantation.

Authors:  Georg Berding; Karin Weissenborn; Meike Dirks; Ralph Buchert; Ann-Katrin Wirries; Henning Pflugrad; Gerrit M Grosse; Carlotta Petrusch; Christian Schütze; Florian Wilke; Martin Mamach; Linda Hamann; Laura B N Langer; Xiao-Qi Ding; Hannelore Barg-Hock; Jürgen Klempnauer; Christian H Wetzel; Mario Lukacevic; Eike Janssen; Mariella Kessler; Frank M Bengel; Lilli Geworski; Rainer Rupprecht; Tobias L Ross
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-12       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.